Daltecan:  A Safety and Efficacy Trial Evaluating the Use of Dalteparin treatment in patients who have malignancies and Venous Thromboembolism (VTE)

The object of this study is to evaluate major bleeding events in patients with cancer who are receiving extended treatment (greater than 6 months, up to 12 months) with Dalteparin as prevention of a recurrent VTE, including the safety and tolerability of treatment in the defined patient population.  Another facet of the study focuses on treatment dosage in patients who present or develop severe renal impairment.

Patients will continue treatment for up to 12 months (52 weeks) or until any of the following occurs: 1) new or recurrent VTE; 2) development of central venous thrombosis of the upper limb(s), neck, or chest; 3) bleeding necessitating permanent discontinuation of anticoagulant therapy; 4) other adverse event necessitating discontinuation of study drug; or 5) withdrawal of informed consent, or 6) removal of subject by primary investigator for any other significant medical reason.